Search Results
- Filter Fund:
- All
- Patents for inventions Ukraine
- Ukraine patents for utility models
- Patents of Ukraine for Industrial Designs
- Patents for inventions abroad
- Applications for inventions
- Certificates for Topographies of Integrated Circuits
- Certificates Ukraine marks for goods and services
- Approved the application for trademark
- Geographical indications (Qualified Appellations of Origin)
| № |
Patent number |
Title of the invention and abstract piece | Date of publication of the patent |
|---|---|---|---|
| 1 | CA2759199A1 |
ITERATIVE MULTI-SCALE METHOD FOR FLOW IN POROUS MEDIA;PROCEDE MULTI-ECHELLE ITERATIF POUR UN ECOULEMENT EN MILIEU POREUX
Computer-implemented iterative multi-scale methods and systems are provided for handling simulation of complex, highly anisotropic, heterogeneous domains. A system and method can be configured to achieve simulation of structures where accurate localization assumptions do not exist. The iterative system and method smoothes the solution field by applying line relaxation in all spatial directions. Th... |
15.04.2010 |
| 2 | IS2610B |
AðFERðÁTILÁAðÁFRAMLEIðAÁSýKLóPRóPýLKARBOXýLSýRUESTERAÁOGÁAFLEIðURÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ | 15.04.2010 |
| 3 | IS2599B |
3-FENýLSúLFóNýL-8-PÃPERASÃN-1-ýL-KÃNóLÃN@OG@LYFJAFRæðILEGA@VIðURKENNDAR@AFLEIðUR@þESS
The present invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders. |
15.04.2010 |
| 4 | IS2600B |
Ný@TRÃASóLPýRIMÃDÃNEFNASAMBöND
The present invention relates to a pyrimidine compound (I) useful as a pharmaceutical intermediate, to a process for preparing said pyrimidine compound, to intermediates used in said process, and to the use of said pyrimidine compound in the preparation of pharmaceuticals. |
15.04.2010 |
| 5 | IS2601B |
TæKI@TIL@Að@LEGGJA@VEIðARFæRI@@EINKUM@TIL@NóTAVEIðA@@Ã@KASSA
A device for laying of fishing utensils, in particular for seining, in a utensil bin on board a vessel. The device comprises a puller (4) adapted for regularized laying of a line, such as an upper line having float elements along a longitudinal edge of the utensil, possibly a lower line, such as a line having weight elements along the opposite longitudinal edge of the utensil, in the bin. The pull... |
15.04.2010 |
| 6 | IS2602B |
PúRÃN@EFNASAMBöND@OG@NOTKUN@þEIRRA@SEM@KANNABÃNóÃð@VIðTAKABINDLAR
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. |
15.04.2010 |
| 7 | IS2603B |
TRÃAMÃð@SETIN@INDóL@@BENSóFúRöN@OG@BENSóþÃóFEN@SEM@HINDRAR@á@NETBóLU@þRÃGLýSERÃð@FLUTNINGSPRóTÃN@@MTP@@OG@EðA@APóFITUPRóTEIN@B@APO@B@@SEYTI
The invention relates to triamide MTP/ApoB inhibitors of the formula 1 wherein R<1>-R<8 >are as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders. |
15.04.2010 |
| 8 | IS2604B |
VATNSSæKNARÁFJöLLIðUBLöNDURÁNOTAðARÁVIðÁMEðFERðÁKúAÁÃÁGELDSTöðUÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ
The present invention provides a mammalian teat dip composition capable of being used during a mammal's dry period comprising a solution of a film-forming polymer blend comprising a first polymer component which is an organic, solvent-soluble, preformed, thermoplastic polyurethane having no reactive isocyanate groups and a second polymer component which is a hydrophilic poly(N-vinyl lactam), said ... |
15.04.2010 |
| 9 | IS2605B |
LOKAð@KERFI@TIL@Að@VERKA@HROGN
A closed system for the continuous or batchwise curing or preservation of fish eggs, comprising: 1. means (1) for drawing in the fish egg mass; 2. means for cutting (2) roe sacs and separating (3) roe from membranes and veins; 3. means (7) for continuously or batchwise mixing roe with preservatives; and 4. means for the transport, storage and maturing of the processed roe mass. |
15.04.2010 |
| 10 | IS2606B |
BINDILLÁTENGDURÁæXLISDREPþæTTIÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ
Tumor necrosis factor related ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them. |
15.04.2010 |
| 11 | IS2607B |
AFLEIðURÁTRYPTAMÃNSÁOGÁHLIðSTæðÁEFNASAMBöNDÁáSAMTÁLYFJAFORSKRIFTUMÁþEIRRAÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ
This invention relates to novel substituted tryptamines and related derivatives, as well as pharmaceutical compositions formulated therefrom. These compounds, compositions and their salts can be used in the manufacture of medicaments for interacting with the melatoninergic system. These compounds and conditions can be used for treating several types of medical conditions, such as central nervous s... |
15.04.2010 |
| 12 | IS2608B |
BóLUEFNISSAMSETNINGÁSEMÁSAMANSTENDURÁAFÁMóTEFNISVAKAÁOGÁPEPTÃðIÁSEMÁHEFURÁóNæMISGLæðANDIÁEIGINLEIKAÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ
The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1-XZXZNXZX-R2, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independently one from the othe... |
15.04.2010 |
| 13 | IS2609B |
NýÁKRISTöLLUðÁFORMÁEFNASAMBANDSÁ(1S-(1A,Á2A,Á3B(1S*,Á2R*),Á5B))-3-(7-((2-(2,4-DÃFLúORóFENýL)SýKLóPRóPýL)AMÃNó)-5-(PRóýLþÃó)-3H-1,2,3-TRÃAZóLó(4,5-D)PýRIMÃDÃN-3-ýL)-5-(2-HýDRóXýETOXý)SýKLóPENTAN-1,2-DÃóLÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ
The invention provides new forms of a chemical compound, processes for their preparation, their use as medicaments, and compositions containing them. |
15.04.2010 |
| 14 | IS2611B |
FULLKOMIðÁFóðURÁFYRIRÁFISKSEIðIÁOGÁAðFERðÁTILÁAðÁBúAÁþAðÁTILÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ
The invention concerns a complete feed composition for fish larvae, characterized in that it has a phospholipid content not less than 8.5 wt. % of dry matter of the feed. |
15.04.2010 |
| 15 | IS2612B |
STöðUGÁFJöLBRIGðIÁN-(3-ETýNYLFENýL)-6,7-BIS)2-METOXýETOXY)-4-QÃNAZóLÃNAMÃNÁHýDRóKLóRÃðS,ÁAðFERðIRÁVIðÁFRAMLEIðSLUÁþESSÁOGÁNOTKUNÁTILÁLYFJAGERðARÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ
The present invention relates to crystalline forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, their production in essentially pure form, and their use. The invention also relates to the pharmaceutical compositions containing the crystalline forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride and to methods of treating hyper... |
15.04.2010 |
| 16 | IS2613B |
ÊTSKIPTÁDÃKETóPÃPERASÃNÁSEMÁOXýTóSÃNBLOKKARÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ
A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. |
15.04.2010 |
| 17 | IS2614B |
AðFERðÁTILÁSTýRINGARÁáÁSÃALSýRUMAGNIÁPRóTÃNAÁSEMÁFRAMLEIDDÁERUÁÃÁSPENDýRAFRUMURæKTÁÁÁÁÁÁÁ
The present invention relates to novel process for the preparation of glycoproteins by mammalian cell culture wherein the sialic acid content of the glycoprotein produced is controlled over a broad range of values by manipulating the cell culture environment. The invention provides for processes in which the sialic acid content of the glycoprotein is modified by changes in cell culture parameters ... |
15.04.2010 |
| 18 | IS2615B |
LAGSKIPTÁEFNIÁTILÁþESSÁAðÁVERJAÁLÃKAMSHLUTAÁOGÁBúNAðURÁSEMÁGERðURÁERÁúRÁþANNIGÁEFNIÁÁÁÁÁÁÁÁÁ
A laminate material includes an upper layer (I) and a lower layer (II) which is joined to the upper layer over substantially the entire surface thereof. The upper layer (I) includes a thin layer of leather material ( 1 ), and the lower layer (II) is a material which can be stretched in two directions. The lower layer (II) includes at least one support layer ( 3 ) which is resilient in two directio... |
15.04.2010 |
| 19 | IS2616B |
LYFJABLANDAÁSEMÁFELURÁÃÁSéRÁLEVóþýROXÃNNATRÃUMÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ
There is provided a stable pharmaceutical formulation comprising (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125 μm and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation, and (c) pregelatinised starch present in an amount of 5 to 30% w/w based upon total weight of the formulation. ... |
15.04.2010 |
| 20 | IS2617B |
FJöLBRIGðAFORMÁAFÁKÃNÃNHRöðUNARÁMóTLYFINUÁ2-(R)-(1-(R)-(3,5-BIS(TRÃFLúORMETýL)FENýL)ETOXý)-3-(S)-(4-FLúOR)FENýL-4-(3-(5-OXó-1H,4H-1,2,4-TRÃASóLó)METýLMORFóLÃNIÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ
This invention is concerned with a novel polymorphic form of the compound 2-(R)-(1-(R) -(3,5-bis(trifluoromethyl) -phenyl)-ethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-5 (-oxo-1H,4H-1,2,4-triazolo) methylmorpholine which is a tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The inst... |
15.04.2010 |